The short answer
The core literature is small and unusually clinical for this field: two 2006 human studies in the Journal of Clinical Endocrinology and Metabolism on CJC-1295, and Raun's 1998 paper establishing ipamorelin's selectivity. There is comparatively little beyond them.
Key facts
- Teichman 2006
- CJC-1295 PK/PD in healthy adults
- Ionescu & Frohman 2006
- Pulsatility under continuous stimulation
- Raun 1998
- Ipamorelin selectivity
- Human data
- Present, unlike most of this library
- Registered trials
- None currently established
- Search terms
- Also NNC 26-0161, GRF(1-29)
A small literature with an unusual composition
Most research peptides have a large rodent literature and no human data. This pair has the opposite profile: a modest number of papers, two of which are controlled human studies in a mainstream endocrinology journal. Volume is low; quality of the core references is comparatively high.
The three papers that matter
Teichman and colleagues, JCEM 2006, on prolonged GH and IGF-I stimulation by CJC-1295 with DAC in healthy adults. Ionescu and Frohman, JCEM 2006, on whether pulsatile GH secretion survives continuous stimulation. Raun and colleagues, European Journal of Endocrinology 1998, establishing ipamorelin as the first selective growth hormone secretagogue. Nearly everything else cites one of these.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
What is absent
Registered interventional trials currently under way, unlike BPC-157, which has a Phase 2 recruiting. Long-term data of any kind. And studies of the combination with the single-agent arms that would be needed to say anything about additivity. The gaps are specific rather than general.
Searching it
CJC-1295 finds the compound directly. GRF(1-29) and sermorelin surface the wider GHRH-analogue literature that gives context. NNC 26-0161 finds ipamorelin's development-era records. Searching only the product names returns a mix of commercial content and the handful of primary papers.
How this category compares within the library
Better human pharmacokinetic data than GHK-Cu, TB-500, DSIP, Semax or Selank. Less clinical development than BPC-157, which has a Phase 2 recruiting. And far less than the incretins, which have outcome trials with tens of thousands of participants. A useful middle position, and an honest one to state.
Frequently asked questions
Is there human data for these compounds?
Yes. Two 2006 studies in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 in healthy adults, which is more than most compounds in this library have.
Are there ongoing trials?
None currently established, unlike BPC-157 which has a Phase 2 recruiting.
What should I search besides the product names?
GRF(1-29) and sermorelin for the GHRH-analogue context, and NNC 26-0161 for ipamorelin's development records.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedTeichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubMedIonescu M & Frohman LA. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedRaun K et al. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 with DAC (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- Storage and Reconstitution for Both CompoundsTwo peptides differing fivefold in mass, stored together but not identical. Why the DAC form's maleimide is the one genuinely reactive feature here.
- What Is CJC-1295? The Two Forms and Their MassesCJC-1295 is a GHRH analogue based on GRF(1-29) with four stabilising substitutions. Two forms exist at different masses, and they are routinely conflated.
- CJC-1295 With and Without DAC3647.2 Da against 3367.9 Da - a 279.3 Da linker separating a week-long half-life from about thirty minutes. How to tell which form you have.
- Half-Life: Why a Covalent Bond Changes EverythingMinutes for native GHRH, about thirty for Mod GRF, days for the DAC form. Each step is a specific chemical intervention against a specific clearance route.
- What Is Ipamorelin? Sequence, Receptor and SelectivityIpamorelin is a five-residue ghrelin receptor agonist, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described as the first selective growth hormone secretagogue.